Accurdx

Based in Jinan, China, Accurdx is a privately held company specializing in the development of in-vitro diagnostic instruments and reagents for clinical diagnosis. Founded in 2017, the firm has established a core technological focus on hemostasis and thrombus detection, providing medical laboratories with precise clinical diagnosis solutions.

The company's product portfolio is structured around several key areas, including coagulation detection systems, specific protein detection systems, reproductive detection systems, and immune detection systems. These products are designed to address the growing demand in the coagulation diagnostics market, which is essential for managing bleeding disorders, thrombotic conditions, and monitoring anticoagulant therapies. The market is seeing increased demand for a range of tests from routine assessments like Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) to more advanced assays such as D-dimer and thromboelastography (TEG).

Accurdx operates on a venture capital-backed business model and has successfully raised capital to fuel its growth. The company has secured $14.4 million in funding from investors including Shandong New Growth Drivers Fund, Addor Capital, and CITIC Medical & Heath Group. Its financing history includes an Early Stage Venture (Series A) round in September 2022 and a Later Stage Venture (Series A1) round in September 2023, indicating the company is generating revenue.

Keywords: in-vitro diagnostics, clinical diagnosis, hemostasis, thrombus detection, coagulation detection, specific protein detection, reproductive detection, immune detection, medical laboratories, diagnostic equipment, venture capital-backed, Shandong New Growth Drivers Fund, Addor Capital, CITIC Medical & Heath Group, diagnostic reagents, clinical solutions, coagulation diagnostics, Prothrombin Time, APTT